S&N sells wound care products
This article was originally published in The Gray Sheet
Executive Summary
Advanced BioHealing acquires Smith & Nephew's Dermagraft tissue-engineered dermal replacement product for full-thickness diabetic foot ulcers and TransCyte temporary wound cover for serious burns. The May 31 product purchase, for undisclosed terms, dovetails with the start-up firm's R&D efforts in tissue engineering; the firm has a pending IDE for a keratinocyte-based bioengineered wound covering that does not require deep frozen storage. S&N indicated its interest in divesting the products in October 2005 to boost its "growth profile" after receiving an FDA "non-approvable" letter for an expanded Dermagraft indication to treat venous leg ulcers...
You may also be interested in...
Financings In Brief
Device VC activity increases
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.